Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043054 | 0.91 | EPHB3 (0.47) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL8048684 | 0.90 | ROCK1 (0.46) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL8042726 | 0.88 | EPHB3 (0.46) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL13099662 | 0.87 | IRAK4 (0.45) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL13099760 | 0.86 | ROCK1 (0.42) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL8048686 | 0.86 | IRAK4 (0.51) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL13099711 | 0.86 | EPHB3 (0.40) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL13099704 | 0.85 | CDK2 (0.42) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL8043069 | 0.84 | GSK3B (0.52) | EPHB3ROCK1LMNAHTTIRAK4 | |
| SCHEMBL8031088 | 0.83 | CDK2 (0.41) | EPHB3ROCK1IRAK4PLK1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2009038385-A2 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | EPHB3 3207/4885ROCK1 250/4885LMNA 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.